---
title: "Wedbush 表示，WAVE 生命科學的 ATS 數據可能會支持其 RNA 編輯平台"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/286602718.md"
description: "Wedbush Securities 預計 Wave Life Sciences 將在 2026 年 ATS 會議上展示其 RestorAATion-2 研究的數據，這可能會增強市場對其 RNA 編輯平台的信心。結果可能表明編輯效率的提高和持續的蛋白質反應，支持 α-1 抗胰蛋白酶的生產。儘管股價下跌 2.6% 至 6.72 美元，Wedbush 仍維持對 Wave Life Sciences 的 “跑贏大盤” 評級，目標價為 15 美元"
datetime: "2026-05-15T18:40:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286602718.md)
  - [en](https://longbridge.com/en/news/286602718.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286602718.md)
---

# Wedbush 表示，WAVE 生命科學的 ATS 數據可能會支持其 RNA 編輯平台

02:40 PM EDT, 05/15/2026 (MT Newswires) -- Wave Life Sciences ( WVE ) is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.

The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.

The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.

Wedbush has an outperform rating and a $15 price target on Wave Life Sciences ( WVE ).

Shares of the company were down 2.6% in Friday trading.

Price: 6.72, Change: -0.18, Percent Change: -2.61

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### 相關股票

- [WVE.US](https://longbridge.com/zh-HK/quote/WVE.US.md)
- [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [BBC.US](https://longbridge.com/zh-HK/quote/BBC.US.md)
- [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md)

## 相關資訊與研究

- [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md)
- [百時美施貴寶向 3 萬名員工全面開放 Anthropic 公司 Claude](https://longbridge.com/zh-HK/news/287085684.md)
- [復宏漢霖：注射用 HLX43 用於治療晚期非小細胞肺癌的國際多中心 2 期臨牀研究完成首例患者給藥](https://longbridge.com/zh-HK/news/287195179.md)
- [WAVE 生命科學公佈了積極的 RestorAATion-2 試驗數據；WVE-006 能夠恢復 M-AAT，減少 Z-AAT，並支持每月給藥方案](https://longbridge.com/zh-HK/news/286818220.md)
- [PepGen 在最新的演示中強調了其 DM1 項目的進展](https://longbridge.com/zh-HK/news/287217817.md)